1. Home
  2. EDD vs TRDA Comparison

EDD vs TRDA Comparison

Compare EDD & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Morgan Stanley Emerging Markets Domestic Debt Fund Inc.

EDD

Morgan Stanley Emerging Markets Domestic Debt Fund Inc.

HOLD

Current Price

$5.48

Market Cap

397.7M

Sector

Finance

ML Signal

HOLD

TRDA

Entrada Therapeutics Inc.

HOLD

Current Price

$12.69

Market Cap

481.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EDD
TRDA
Founded
2007
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
397.7M
481.6M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
EDD
TRDA
Price
$5.48
$12.69
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$20.00
AVG Volume (30 Days)
489.5K
196.5K
Earning Date
01-01-0001
05-25-2026
Dividend Yield
7.52%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$25,421,000.00
Revenue This Year
N/A
$39.97
Revenue Next Year
N/A
$53.29
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.28
$4.93
52 Week High
$6.18
$13.99

Technical Indicators

Market Signals
Indicator
EDD
TRDA
Relative Strength Index (RSI) 28.18 55.05
Support Level $5.45 $9.78
Resistance Level $5.69 N/A
Average True Range (ATR) 0.10 0.92
MACD -0.06 0.09
Stochastic Oscillator 14.29 53.40

Price Performance

Historical Comparison
EDD
TRDA

About EDD Morgan Stanley Emerging Markets Domestic Debt Fund Inc.

Morgan Stanley Emerging Markets Domestic Debt Fund Inc is a closed-end management investment company. The company's primary investment objective is to seek a high level of current income, with a secondary investment objective of long-term capital appreciation. It seeks to achieve investment objectives by investing, under normal circumstances, at least 80% of its managed assets in emerging markets domestic debt. The fund's portfolio includes sovereign, quasi-sovereign, corporate bonds in emerging markets.

About TRDA Entrada Therapeutics Inc.

Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

Share on Social Networks: